Trials / Completed
CompletedNCT00161928
Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants
A Randomized, Open-Label Trial of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 2 Months – 6 Months
- Healthy volunteers
- Accepted
Summary
The primary aim of the study is to show that NeisVac-C does not influence the seroconversion rates induced by hepatitis B (Hep B), inactivated polio (IPV) and acellular pertussis (aP) vaccines in infants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT) |
Timeline
- Start date
- 2002-04-01
- Completion
- 2003-01-01
- First posted
- 2005-09-13
- Last updated
- 2015-05-21
Locations
14 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT00161928. Inclusion in this directory is not an endorsement.